Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 6 Date: 16 May 2022
Reviewer:  Keita Harada
Reviewer's report:
1. The authors clearly stated that this study was funded by New Horizon Health Technology
Co. Ltd. on page 6, line 11. In addition, they also described in revise letter that reagentes for
experiments were provided by NHHT Co. Ltd. Despite those, why is there no COI?? Is this a
matter of amount (too small)? I am not saying that I will not accept the manuscript when they
have COI with corporation. Please disclose to avoid misunderstanding. Othewise, please explain
the details of the contradiction.
2. Because the novel evaluation described in this paper was for detecting cancer, interpreting
that benign polyps were the cause of the marker elevation in these two patients, rather than the
resected advanced cancer, would affect the reliability of this paper. I think you were good to
delete figure 6.
Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 6 Date: 16 May 2022
Reviewer:  Keita Harada
Reviewer's report:
1. The authors clearly stated that this study was funded by New Horizon Health Technology
Co. Ltd. on page 6, line 11. In addition, they also described in revise letter that reagentes for
experiments were provided by NHHT Co. Ltd. Despite those, why is there no COI?? Is this a
matter of amount (too small)? I am not saying that I will not accept the manuscript when they
have COI with corporation. Please disclose to avoid misunderstanding. Othewise, please explain
the details of the contradiction.
2. Because the novel evaluation described in this paper was for detecting cancer, interpreting
that benign polyps were the cause of the marker elevation in these two patients, rather than the
resected advanced cancer, would affect the reliability of this paper. I think you were good to
delete figure 6.
Please review this paper.
user
Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 6 Date: 16 May 2022
Reviewer:  Keita Harada
Reviewer's report:
1. The authors clearly stated that this study was funded by New Horizon Health Technology
Co. Ltd. on page 6, line 11. In addition, they also described in revise letter that reagentes for
experiments were provided by NHHT Co. Ltd. Despite those, why is there no COI?? Is this a
matter of amount (too small)? I am not saying that I will not accept the manuscript when they
have COI with corporation. Please disclose to avoid misunderstanding. Othewise, please explain
the details of the contradiction.
2. Because the novel evaluation described in this paper was for detecting cancer, interpreting
that benign polyps were the cause of the marker elevation in these two patients, rather than the
resected advanced cancer, would affect the reliability of this paper. I think you were good to
delete figure 6.
assistant